TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives $12.08 Consensus PT from Analysts

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has received a consensus recommendation of “Buy” from the nine brokerages that are covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $11.79.

A number of research analysts have commented on TLSI shares. Roth Mkm started coverage on TriSalus Life Sciences in a research note on Monday, November 11th. They set a “buy” rating and a $11.00 price target on the stock. Northland Securities began coverage on TriSalus Life Sciences in a research note on Friday, October 25th. They set an “outperform” rating and a $12.50 target price on the stock. Canaccord Genuity Group lowered their target price on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 15th. Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Finally, Cantor Fitzgerald initiated coverage on shares of TriSalus Life Sciences in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price objective for the company.

TriSalus Life Sciences Price Performance

Shares of TLSI opened at $4.05 on Friday. The firm has a 50-day simple moving average of $4.14 and a two-hundred day simple moving average of $4.92. TriSalus Life Sciences has a 1-year low of $3.50 and a 1-year high of $10.42. The stock has a market cap of $123.48 million, a PE ratio of -1.63 and a beta of 0.56.

Insider Transactions at TriSalus Life Sciences

In other TriSalus Life Sciences news, major shareholder Equity Ab Frankenius bought 62,972 shares of the firm’s stock in a transaction that occurred on Tuesday, December 17th. The stock was purchased at an average price of $3.97 per share, for a total transaction of $249,998.84. Following the completion of the purchase, the insider now directly owns 6,230,748 shares in the company, valued at $24,736,069.56. This trade represents a 1.02 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders bought 70,012 shares of company stock valued at $281,235. Insiders own 32.80% of the company’s stock.

Institutional Trading of TriSalus Life Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TLSI. Walleye Capital LLC purchased a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at $66,000. Virtu Financial LLC acquired a new stake in shares of TriSalus Life Sciences during the third quarter worth about $92,000. Vestcor Inc purchased a new stake in shares of TriSalus Life Sciences in the 3rd quarter valued at about $108,000. MSD Partners L.P. purchased a new stake in shares of TriSalus Life Sciences in the 3rd quarter valued at about $184,000. Finally, Wolverine Asset Management LLC acquired a new stake in shares of TriSalus Life Sciences in the 2nd quarter valued at about $240,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.